Login
Companies $AKBA
$0.47 +$0.02 (5.1%) After hours
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

akebia.com

What Do They Do?

Sells oral medicines for anemia and other complications of kidney disease to people with kidney disease.

How Do They Make Money?

Akebia sells Auryxia and Vafseo to customers, who pay when they receive the products. Partners also pay upfront license fees when they receive rights, milestone payments and royalties on licensed-product sales, and Akebia earns revenue from products it supplies to partners.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product revenue, net
Sold outright

96%
FY2022: 60%
License, collaboration and other revenue
3.8%
FY2022: 40%

Who Are Their Customers?

Dialysis organizations and distribution customers buy Auryxia and Vafseo for resale to healthcare providers and patients; partners pay Akebia under license, collaboration and product-supply agreements.

Do Revenues Turn Into Profits?

Not on paper. It lost $5.3M in FY2025, but brought in more cash than it spent: $67.7M of free cash flow.

Operating income, FY2025
10% of revenue
▲ Turned profitable vs FY2024 (−$50.5M, −32%)
Net income, FY2025
−2% of revenue
▲ +92% (Loss) vs FY2024 (−$69.4M, −43%)
Free cash flow, FY2025
29% of revenue
▲ Turned profitable vs FY2024 (−$40.7M, −25%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −37%
vs $58.8M in Q3 FY2025
Net income
▼ Turned to a loss
vs $540K in Q3 FY2025
Product revenue, net share of revenue vs 96.6% in Q3 FY2025
  • Oct 21, 2026 Nasdaq notified Akebia of a minimum bid-price deficiency Akebia has until April 19, 2027, to regain compliance; otherwise, its shares could face delisting.

Vafseo reached the U.S. market Vafseo moved from a medicine under U.S. regulatory review to a U.S.-marketed treatment for anemia in adults on dialysis.

Revenue over time
Product revenue, net License, collaboration and other revenue
$500M$250M$0

Who Do They Compete With?

Competes with Amgen, Johnson & Johnson, CSL Vifor, Astellas Pharma, Teva Pharmaceuticals, Stada Arzneimittel, Hexal, Sandoz, Roche, Bayer HealthCare, Sanofi, Fresenius Medical Care North America, Shire Pharmaceuticals Group, OPKO Health, Unicycive, and Ardelyx

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support